Lineage Cell Therapeutics Reports Positive 36-Month Phase 1/2a Results for RG6501 in OpRegen Trial

Lineage Cell Therapeutics, Inc. (LCTX) reported positive 36-month Phase 1/2a results for its OpRegen therapy, showing sustained vision improvements in patients with geographic atrophy, a form of age-related macular degeneration. The company also treated its first chronic spinal cord injury patient in a new OPC1 trial and partnered with William Demant Invest A/S to develop a cell transplant program for sensorineural hearing loss. LCTX holds $42.3 million in cash and continues to invest in R&D and manufacturing capabilities.